At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 119 enrolled
Drug / intervention
AZD2171drug
Likely dose
AZD2171 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients With Advanced Solid Tumours
In Brief
A Phase 2 clinical trial evaluating AZD2171 for Tumors. Completed, enrolled 119 participants across 6 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesGermany, Netherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedDec 2005
Primary CompletionJan 2007
Study CompletionApr 2011
TodayJul 2026
First PostedDec 12, 2005
Enrollment StartNov 1, 2005
Primary CompletionJan 1, 2007
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.6 years ago
Interventions
AZD2171drug
30 mg \& 45 mg oral tablet